Coverage from AAPS PharmSci 360 and CPHI Milan featured discussion about impurities, devices, and supply resilience. This week also included topics such as AI accountability, oral peptides, and new licensing deals.
News|Articles|February 2, 2005
- Pharmaceutical Technology-02-02-2005
- Volume 29
- Issue 2
Using Extrusion-Spheronization to Develop Controlled-Release Formulations of Azithromycin
Extrusion-spheronization and pellet compression are effective means of developing first-order kinetic, controlled-release drug delivery systems of azithromycin (AZI). The authors prepared, evaluated, and optimized AZI formulations and assessed the stability of the selected formulation under accelerated storage conditions.
Advertisement
Articles in this issue
almost 22 years ago
Correcting the Coursealmost 22 years ago
February 2005almost 22 years ago
Good Work and True: USP Prepares for Convention 2005almost 22 years ago
Contract Manufacturers Getting Squeezedalmost 22 years ago
In the Spotlight-February 2005almost 22 years ago
Emerging Analytical Technology: Moving from the Lab to the Linealmost 22 years ago
Drug Safety Fears May Limit Reimporting and Shape R&Dalmost 22 years ago
In Defense of USP Singlet TestingAdvertisement
Related to this article
The FDA grants accelerated approval to subcutaneous amivantamab for head and neck cancer, extending the IV-to-subcutaneous shift in biologics formulation.
Almac Clinical Services’ clinical supply strategy won the 2026 CPHI Award for Supply Chain Excellence. Nishma Patel, supply chain solutions manager, explains the benefits and challenges of the company’s just-in-time manufacturing solution.
Vivek Gupta of Duquesne University explains at AAPS PharmSci 360 why device decisions can't wait and why excipient makers must test beyond drug molecules.
This week addressed AI accountability, CPHI award winners, NFC anticounterfeiting, first-in-class FDA approvals, and a shelved FDA voucher pilot lead this week’s roundup.
Cole and Jaenisch explain why defending against AI poisoning in pharma manufacturing calls for a data steward role, immutable instruction ledgers, and automation.
Terry Katz, CEO and co-founder of ForgeStop Technology Corporation, explains how the company’s product is worth the investment by protecting products and patients.
The FDA has shelved its National Priority Voucher pilot, leaving sponsors that built CMC and launch-readiness plans around 1- to 2-month reviews facing uncertain timelines.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Manufacturing Intelligence: AI Poisoning Demands Pharma Data Stewards
2
CPHI Pharma Award Winner: Drug Delivery, Devices, & Packaging
3
Investing in Protecting Pharma Products
4
Signs Point to FDA Shelving Priority Voucher Pilot, Stalling Fast-Track Drug Reviews
5